HUNTINGTON BEACH, Calif.
Jan. 8, 2013
/PRNewswire/ -- Absorption Pharmaceuticals, makers of the world's first FDA-Approved topical treatment for
, Promescent, announced today that
Laurence A. Levine
, MD will assume the role of Chief Medical Officer (CMO). Dr. Levine will oversee the company's growth and education efforts, with a focus on getting Promescent written into protocols as a top-line
treatment for premature ejaculation
"We're thrilled to have such a highly respected and knowledgeable physician join our team," says
, CEO of Absorption Pharmaceuticals. "We have been growing rapidly due to Promescent's proven effectiveness and securing Dr. Levine– whom has already provided invaluable assistance in reaching key opinion leaders in sexual medicine– adds to the credibility of this revolutionary product in the sexual medicine category. We look forward to the ongoing adoption of Promescent as the primary medical
solution for premature ejaculation
Dr. Levine received his medical degree from the
University of Colorado
Medical School, followed by a residency in general surgery at Tufts-New England Medical Center and in urology at the Harvard Program in Urology at Brigham and Women's Hospital in Boston. He has made a substantial contribution to the medical press in the form of peer-reviewed articles, books, book chapters, and Internet publications regarding male sexual dysfunction, fertility, chronic orchialgia and reconstructive urology. Currently, Dr. Levine is a professor of urology at the
Medical Center in
, and is in private practice with Uropartners, LLC. He has received multiple awards and honors; and served as a past-president of the Sexual Medicine Society of
and the Chicago Urological Society.
"I am very excited to join Absorption Pharmaceuticals as Chief Medical Officer," says Dr. Levine. "Promescent is a ground-breaking, unrivaled product and doctors across the country are delighted to have a solution to a problem that previously has not received the attention it deserves. As an early adopter of the product as treatment for my patients with PE, I'm proud to lead the charge in spreading awareness of Promescent to the medical community."